Kailera Targets Structure's '183 Patent in European Dispute, Escalating Section 1782 Discovery Case

Kailera Targets Structure's '183 Patent in European Dispute, Escalating Section 1782 Discovery Case

The legal and clinical battle in the once-daily oral and injectable GLP-1 receptor agonist market has escalated significantly between newly public Kailera Therapeutics, Inc. (NASDAQ: KLRA) and Structure Therapeutics, Inc. (NASDAQ: GPCR).

The Section 1782 Discovery Battle

Kailera has launched a major legal challenge in Europe targeting Structure's European patent EP 4 230 183 B1 (the "'183 patent")¹, which covers small-molecule GLP-1 receptor agonists like Structure's lead Phase 3 candidate, aleniglipron.

To support its European patent challenge, Kailera filed an ex parte application for Section 1782 discovery assistance in the U.S. District Court for the Northern District of California (Case No. 3:2026mc80216) on July 22, 2026. If granted by Judge Thomas S. Hixson, the order would compel Structure and its affiliate Gasherbrum Bio, Inc. to hand over internal documents and communications for use in the European patent fight. As of late August 2026, the court has granted several pro hac vice motions, but a final ruling on the ex parte application remains pending.

Kailera's Post-IPO Market Position and Pipeline

Kailera completed one of the largest biotechnology IPOs in recent memory in April 2026. However, its stock has experienced a sharp post-IPO decline, falling approximately 28.8% to hit a new 52-week low of $16.21 on August 31, 2026, resulting in a market capitalization of $2.10 billion.

Despite the stock pressure, analysts maintain a highly positive "Moderate Buy" consensus with a mean target price of $42.40, pointing to a robust ex-China pipeline licensed from Jiangsu Hengrui Pharmaceuticals:

• Ribupatide (KAI-9531): A GLP-1/GIP dual agonist anchoring the global Phase 3 KaiNETIC program of over 4,700 participants (with data expected in 2028). A U.S. Phase 2b high-dose trial of ribupatide is fully enrolled, with data expected in mid-2027. An oral formulation of ribupatide is scheduled to enter global Phase 3 trials in H1 2027.
• KAI-7535: An oral small-molecule GLP-1 agonist with Phase 2 data expected in 2027.
• KAI-4729: A triple-agonist (GLP-1/GIP/glucagon) scheduled to enter Phase 1 trials by the end of 2026.

Financial Runway and Takeout Potential

Kailera reports $0 in TTM revenue. For the second quarter ending June 30, 2026, the company posted an operating loss of $121.4 million and a net loss of $111.3 million. Kailera holds $130.3 million in cash against $10.2 million in total debt, though its broader cash and marketable securities portfolio is estimated at $1.17 billion, providing a comfortable financial runway into mid-2028.

Given its late-stage ex-China rights to a highly competitive GLP-1/GIP asset and its depressed valuation, Kailera has emerged as a prime acquisition target for major pharmaceutical firms seeking an immediate foothold in the metabolic space (such as Pfizer, AstraZeneca, Merck, or AbbVie).